Closing the Gap: Optimizing AML Treatment in Aging Adults

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 44 Minutes

Overview

Older adults with acute myeloid leukemia represent a highly heterogeneous population in whom age, comorbidities, disease biology, and functional status all influence treatment decisions and outcomes. This educational session explores the evolving treatment landscape for aging adults with AML, with emphasis on risk stratification, fitness assessment, and the integration of intensive and lower‑intensity therapies. Participants will examine evidence supporting newer regimens, apply geriatric and safety considerations to real‑world cases, and develop individualized treatment strategies that balance efficacy, toxicity, and patient goals of care.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

  1. Examine both the complexities and promising developments in the treatment of older adults with acute myeloid leukemia (AML)
  2. Describe strategies for incorporating evidence-based treatment options into personalized treatment plans for older adults with AML
  3. Identify medication safety and supportive care strategies that can be tailored to an older adult AML patient population             
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
01/20/2026
Course expires: 
01/23/2027
Cost:
$0.00
Rating: 
0

Faculty

Bradley Yelvington, PharmD, BCOP

Clinical Pharmacist Specialist
Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, TN

Dr. Yelvington is a Board-Certified Oncology Pharmacist practicing since 2017 at Vanderbilt University Medical Center in Adult Malignant Hematology. He received his Doctorate of Pharmacy from the Auburn University Harrison School of Pharmacy in 2015 and completed residencies in Pharmacy Practice at Greenville Health Systems and in Oncology at Wake Forest Baptist Health.

In addition to patient care responsibilities at Vanderbilt, he serves on the Hematology/Oncology Pharmacy and Therapeutics subcommittee, is an involved preceptor of pharmacy students and residents, and is active in multiple national hematology/oncology focused organizations.  His current areas of research interest include optimization of high dose methotrexate administration and supportive care and management of complex chemotherapy drug-drug interactions in lymphoma patients

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Bradley Yelvington, PharmD, BCOP   discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients during the past 24 months.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above